Media coverage about NeuroMetrix (NASDAQ:NURO) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. NeuroMetrix earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned media stories about the medical device company an impact score of 47.1785903606569 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of NeuroMetrix (NASDAQ NURO) traded down 3.02% during mid-day trading on Tuesday, reaching $1.93. 49,744 shares of the company’s stock traded hands. The firm’s 50-day moving average is $2.37 and its 200 day moving average is $1.57. NeuroMetrix has a one year low of $0.38 and a one year high of $4.50. The firm’s market cap is $3.59 million.
NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings data on Thursday, July 20th. The medical device company reported ($2.49) EPS for the quarter, topping analysts’ consensus estimates of ($2.83) by $0.34. The firm had revenue of $4.31 million during the quarter, compared to analysts’ expectations of $4.40 million. NeuroMetrix had a negative return on equity of 209.56% and a negative net margin of 83.92%. Analysts predict that NeuroMetrix will post ($11.20) earnings per share for the current year.
NURO has been the topic of a number of analyst reports. Zacks Investment Research downgraded shares of NeuroMetrix from a “hold” rating to a “sell” rating in a research report on Wednesday, April 26th. ValuEngine downgraded shares of NeuroMetrix from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, HC Wainwright set a $16.00 target price on shares of NeuroMetrix and gave the stock a “buy” rating in a research report on Thursday, June 15th.
WARNING: This report was reported by BBNS and is the sole property of of BBNS. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://baseballnewssource.com/markets/neurometrix-nuro-earning-somewhat-favorable-press-coverage-analysis-finds-updated/1308405.html.
NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.
Receive News & Ratings for NeuroMetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix Inc. and related companies with our FREE daily email newsletter.